Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction

Fig. 6

Transfection with specific Anti-hsa-miR inhibitors upregulate MCL-1 and JAK3 protein expression and rescues the cells from apoptosis. The percentage of CD8+ T cells in a freshly isolated PBMC sample is depicted from one RCC patient (a). PBMCs from RCC patients were transfected with 10, 50 and 250 nM Anti-hsa-miR-29b or Anti-hsa-miR-198 inhibitor and 10 and 250 nM scrambled miR control (SCR), as outlined in “Methods” section. After 48 h cell lysates were generated and western blots performed to quantitate MCL-1 (b) and JAK3 (c) protein levels. Three independent experiments were performed and gels showing MCL-1 and JAK3 protein levels were scanned and quantified. **p < 0.005 and *p < 0.01 versus cells only treated with 250 nM scrambled miR control

Back to article page